Natco Pharma’s net gain increased 4.9 percent to ₹ 406 million rupees, compared to ₹ 386 million rupees in the corresponding quarter of the previous financial year. Hyderab -based company’s total revenues increased to ₹ 1,287 million rupees in the quarter under review, against ₹ 1,110 million rupees in the period of the previous year.
Duration of the quarter, Natco Pharma, a charge for deterioration of ₹ 50 million rupees in the commercial relationship of crop health sciences with property, plant and machinery, a coal adjustment of approximately ₹ 25 million rupees in its US subsidiary, separated from higher R&D expenses.
Throughout the year of the 2015 fiscal year, it registered total consolidated income of ₹ 4,784 million rupees, against ₹ 4,127 million rupees last year, reflecting a growth of 16 percent.
Only the gain of the year, for consolidation, was ₹ 1,883 million rupees, against ₹ 1,388 million rupees last year, registering a growth of 36 percent. “The company has registered its greatest consolidated income and profits this financial year. This is the result of decades of our diligence,” Natco said in a statement in Wedede.
As of March 2025, the company had cash or around ₹ 3,000 million rupees, since it prepares for winds against its commercial duration of the United States in the financial year 2025-26. The company estimates a possible revenue drop in 20 percent and profits by 30 percent due to geopolitical uncertainties and price pressure in its basic products portfolio in the US. UU. And higher R & D.
Posted on May 28, 2025
